Key Highlights

  • LENZ Therapeutics (NASDAQ:LENZ) is listed at USD 3.41, below its 52-week low of USD 3.46 and 93.1% below its high of USD 49.16.
  • LENZ reported second-quarter revenue of USD 5.5 million, of which USD 1.7 million was VIZZ product sales and USD 3.75 million was license revenue, while selling expenses reached USD 39.4 million.
  • Over 60% of ePharmacy patients bought multiple packs and the cohorts are tracking to five packs a year, and a telehealth channel launched in July.
  • Cash was USD 258.4 million at March 31, more than double the USD 110.914 million market value, and the price of USD 3.41 is below the USD 3.46 52-week low.

The Latest Verified Updates

No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. LENZ Therapeutics sells VIZZ, the first aceclidine eye drop for presbyopia, and reported second-quarter 2026 revenue of USD 5.5 million, including USD 1.7 million of product sales and USD 3.75 million of license revenue. Selling, general and administrative expenses were USD 39.4 million in the quarter, so the launch is consuming far more cash than it generates. More than 60% of patients in its main ePharmacy channel purchased multiple monthly packs and the Q4 2025 and Q1 2026 cohorts are tracking to five packs per patient a year, and a telehealth channel began in July.

Short Interest, Volume and the Data

Cash, cash equivalents and marketable securities were USD 258.4 million at March 31, which is about 2.3 times the USD 110.914 million market value, simple arithmetic, although the second quarter burned a large part of it. Product sales were USD 1.7 million in both the first and second quarters, which means launch revenue is flat while spending is high. The price of USD 3.41 is below the USD 3.46 low on the screen and about 93% below the USD 49.16 high. Simple arithmetic puts the prior close near USD 3.62, so the day's move is about USD 0.21 a share. The listed price is below the screen's 52-week low of USD 3.46, which implies a fresh low, and it sits 93.1% below the high of USD 49.16. Volume of 1.037 million shares against a three-month average of 829,742 is 1.2 times, which is above average; in a heavily shorted stock, high volume can reflect short covering or new short selling, so volume alone does not reveal direction.

Risks and What to Watch

A flat launch, heavy selling spending and a stock at a new low make the equity highly sensitive to prescription data. What to watch next: quarterly VIZZ prescriptions, cash burn and the telehealth channel. This is information only and not investment advice. Oil traded above USD 100 a barrel as Russia-Ukraine and Middle East developments and stalled Strait of Hormuz talks kept supply risks elevated.

Where Things Stand

Market conditions frame the day: oil traded above USD 100, the big banks report this week and heavily shorted technology names remain volatile. LENZ Therapeutics (NASDAQ:LENZ) is moving with a flat product launch against high spending. A drop in a heavily shorted stock can reverse quickly, so the balance of evidence favors waiting for confirmation from filings and the next session. Direction remains unknown, and the next catalyst is quarterly VIZZ prescriptions, cash burn and the telehealth channel. Check the underlying filings first, verify the latest filings before acting, and treat the figures as a snapshot.